- Time of issue:2019-08-05 00:00:00
Livzon is Always Committed to Human Healthcare
Livzon Pharmaceutical Group Inc.,established in January 1985 with registered capital of 935 million yuan，is a comprehensive pharmaceutical group company integrating pharmaceutical R&D,production and sales，with more than 8,000 employees and is one of the few listed pharmaceutical companies with A+H shares in the capital market.In 2021，the revenue of the company is 12.06 billion yuan （$ 1.88 billion），the net profit is 1.78 billion yuan （$ 278 million），and the R&D investment is 1.52 billion yuan（$ 237 million）.
Livzon continues to make breakthroughs in areas of APIs，chemical drugs，traditional Chinese medicine,biological drugs and in vitro diagnostics,etc.Involving digestive，cardio-cerebrovascular,reproductive endocrinology,psychotropic/neurological and other fields.The company continues to focus on innovation and high-barrier complex preparations,and has launched blockbuster products such as leuprorelin and ILaprazole,achieving volume growth in the digestive and assisted reproductive fields.
The development of Livzon is inseparable from the continuous joining of excellent talents and continuous high growth of R&D investment.The company has built a full range of scientists network and will continues to recruit top talents worldwide.The research and development teamof Livzon has hundreds of PhDs and high-end R&D personnel.Livzon will keep focusing on the field of life and health，constantly improve the quality of life of patients，continue to shoulder social responsibility，actively participate in public welfare undertakings and accelerate the globalization of Livzon.